



Carprieve Caplets

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations
Revision Date: 04/13/2016 Date of Issue: 04/13/2016

Version: 1.0

SECTION 1: IDENTIFICATION

1.1. Product Identifier

Product Form: Mixture

Product Name: Carprieve Caplets

Product Code: ANADA 200-498

1.2. Intended Use of the Product

Use of the Substance/Mixture: Non-steroidal anti-inflammatory drug. Carprofen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopaedic surgeries in dogs.

1.3. Name, Address, and Telephone of the Responsible Party

Supplier

Norbrook, Inc.

9401 Indian Creek Parkway – Ste. 680

Overland Park, KS 66210

Phone: 913 599 5777

Fax: 913 599 5766

Manufacturer

Norbrook Laboratories Ltd,

Station Works, Newry, Co.Down,

N.Ireland, BT35 6JP.

Telephone No. +44 (0)28 3026 4435

Fax No. +44 (0)28 3026 1721

E-Mail: enquiries@norbrook.co.uk

1.4. Emergency Telephone Number

Emergency Number : 913 599 5777

SECTION 2: HAZARDS IDENTIFICATION

2.1. Classification of the Substance or Mixture

GHS-US Classification

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(6)(vii).

2.2. Label Elements

No labeling is required as defined in the 29 CFR 1910.1200(b)(5)(iii).

2.3. Other Hazards

Exposure may aggravate those with pre-existing eye, skin, or respiratory conditions.

2.4. Unknown Acute Toxicity (GHS-US)

No data available

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substance

Not applicable

3.2. Mixture

Name	Product Identifier	%	GHS-US classification
Carprofen	(CAS No) 53716-49-7	Proprietary	Acute Tox. 3 (Oral), H301

Full text of H-phrases: see section 16

The specific chemical identity and/or exact percentage of composition have been withheld as a trade secret [29 CFR 1910.1200]

SECTION 4: FIRST AID MEASURES

4.1. Description of First-aid Measures

First-aid Measures General: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label if possible).

First-aid Measures Inhalation: The risk of inhalation exposure is negligible when product is in its final packaged form. If exposed and become symptomatic, move to fresh air and get medical attention if symptoms persist.

First-aid Measures After Skin Contact: Remove contaminated clothing. Rinse affected area with water for at least 5 minutes. Obtain medical attention if irritation persists. Wash contaminated clothing before reuse.

First-aid Measures After Eye Contact: The risk of eye exposure is negligible when product is in its final packaged form. If eye contact occurs, flush immediately with water for at least 15 minutes. If easy to do, remove contact lenses. Get medical attention.

First-aid Measures After Ingestion: Ingestion is not an anticipated route of exposure. If accidental ingestion occurs, flush mouth out with water and get medical attention.

Carprieve Caplets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

4.2. Most Important Symptoms and Effects Both Acute and Delayed

Symptoms/Injuries: Pharmaceutical. When handling in workplace settings, in quantities that are most likely above the therapeutic dose, this product may be harmful if absorbed through the eyes, skin, or respiratory tract. Please refer to the package insert for more detailed information.

Symptoms/Injuries After Inhalation: Due to the product's final form, inhalation is an unlikely route of exposure.

Symptoms/Injuries After Skin Contact: None expected under normal conditions of use.

Symptoms/Injuries After Eye Contact: None expected under normal conditions of use.

Symptoms/Injuries After Ingestion: Pharmaceutical. Harmful if swallowed. Ingestion is likely to be harmful or have adverse effects.

Chronic Symptoms: None expected under normal conditions of use.

4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed

If you feel unwell, seek medical advice (show the label where possible).

SECTION 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing Media

Suitable Extinguishing Media: Use extinguishing media appropriate for surrounding fire.

Unsuitable Extinguishing Media: None known.

5.2. Special Hazards Arising From the Substance or Mixture

Fire Hazard: Not considered flammable but may burn at high temperatures.

Explosion Hazard: Product itself is not explosive but if dust is generated, dust clouds suspended in air can be explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

5.3. Advice for Firefighters

Precautionary Measures Fire: Exercise caution when fighting any chemical fire. Under fire conditions, hazardous fumes will be present.

Firefighting Instructions: Use water spray or fog for cooling exposed containers. In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.

Protection During Firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal Precautions, Protective Equipment and Emergency Procedures

General Measures: Use only as directed. Avoid contact with skin, eyes and clothing. Avoid generating dust.

6.1.1. For Non-Emergency Personnel

Protective Equipment: Use appropriate personal protection equipment (PPE).

Emergency Procedures: Evacuate unnecessary personnel.

6.1.2. For Emergency Responders

Protective Equipment: Equip cleanup crew with proper protection.

Emergency Procedures: Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit.

6.2. Environmental Precautions

Avoid release to the environment.

6.3. Methods and Materials for Containment and Cleaning Up

For Containment: Contain and collect as any solid.

Methods for Cleaning Up: Clean up spills immediately and dispose of waste safely. Avoid actions that cause dust to become airborne during clean-up such as dry sweeping or using compressed air. Use HEPA vacuum or thoroughly wet with water to clean-up dust. Use PPE described in Section 8. Contact competent authorities after a spill.

6.4. Reference to Other Sections

See Heading 8. Exposure controls and personal protection. For further information refer to section 13.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for Safe Handling

Additional Hazards When Processed: Product is in pill form, but contains substances that are combustible dusts. If these substances in their powder form are allowed to accumulate, dispersed in sufficient quantities in air, and in the presence of an ignition source, it may cause a dust explosion.

Hygiene Measures: This SDS is for a pharmaceutical agent - Handling of this product in its final form presents minimal occupational exposure risk. In an occupational setting, handle in accordance with good industrial hygiene and safety procedures. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Use appropriate personal protective equipment when handling and observe good personal hygiene measures after handling.

Carprieve Caplets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

7.2. Conditions for Safe Storage, Including Any Incompatibilities

Technical Measures: Comply with applicable regulations.

Storage Conditions: Store in a dry, cool and well-ventilated place. Keep container closed when not in use. Keep/Store away from direct sunlight, extremely high or low temperatures and incompatible materials.

Incompatible Products: Strong acids, strong bases, strong oxidizers.

Storage Temperature: Store at 15 - 30 °C (59 - 86 °F)

7.3. Specific End Use(s)

Non-steroidal anti-inflammatory drug. Carprofen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopaedic surgeries in dogs.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control Parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), AIHA (WEEL), NIOSH (REL), or OSHA (PEL).

8.2. Exposure Controls

Appropriate Engineering Controls

: Avoid creating or spreading dust. Ensure adequate ventilation, especially in confined areas. Emergency eye wash fountains and safety showers should be available in the immediate vicinity of any potential exposure. Ensure all national/local regulations are observed.

Personal Protective Equipment

: Avoid all unnecessary exposure. Gloves. Protective clothing. Protective goggles. Insufficient ventilation: wear respiratory protection.



Materials for Protective Clothing

: Chemically resistant materials and fabrics.

Hand Protection

: Wear chemically resistant protective gloves.

Eye Protection

: Chemical goggles or safety glasses.

Skin and Body Protection

: Wear suitable protective clothing. Wash contaminated clothing before reuse.

Respiratory Protection

: In case of inadequate ventilation, oxygen deficient atmosphere, or where exposure levels are not known wear approved respiratory protection.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on Basic Physical and Chemical Properties

Physical State	: Solid
Appearance	: Yellow
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Evaporation Rate	: No data available
Melting Point	: No data available
Freezing Point	: No data available
Boiling Point	: No data available
Flash Point	: No data available
Auto-ignition Temperature	: No data available
Decomposition Temperature	: No data available
Flammability (solid, gas)	: No data available
Vapor Pressure	: No data available
Relative Vapor Density at 20°C	: No data available
Relative Density	: No data available
Solubility	: No data available
Partition Coefficient: N-Octanol/Water	: No data available
Viscosity	: No data available

9.2. Other Information

No additional information available

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity: Hazardous reactions will not occur under normal conditions.

Carprieve Caplets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

- 10.2. Chemical Stability:** Stable at standard temperature and pressure.
- 10.3. Possibility of Hazardous Reactions:** Hazardous polymerization will not occur.
- 10.4. Conditions to Avoid:** Direct sunlight, extremely high or low temperatures, open flames, sources of ignition and incompatible materials. Avoid creating or spreading dust.
- 10.5. Incompatible Materials:** Strong acids, strong bases, strong oxidizers.
- 10.6. Hazardous Decomposition Products:** Thermal decomposition generates: Carbon oxides (CO, CO₂). Sodium oxides.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information on Toxicological Effects

Acute Toxicity: Oral: Not classified.

Carprofen (53716-49-7)	
LD50 Oral Rat	74 mg/kg

Skin Corrosion/Irritation: Not classified

Serious Eye Damage/Irritation: Not classified

Respiratory or Skin Sensitization: Not classified

Germ Cell Mutagenicity: Not classified

Carcinogenicity: Not classified

Reproductive Toxicity: Not classified

Specific Target Organ Toxicity (Single Exposure): Not classified

Specific Target Organ Toxicity (Repeated Exposure): Not classified

Aspiration Hazard: Not classified

Symptoms/Injuries After Inhalation: Due to the product's final form, inhalation is an unlikely route of exposure.

Symptoms/Injuries After Skin Contact: None expected under normal conditions of use.

Symptoms/Injuries After Eye Contact: None expected under normal conditions of use.

Symptoms/Injuries After Ingestion: Pharmaceutical. Harmful if swallowed. Ingestion is likely to be harmful or have adverse effects.

Chronic Symptoms: None expected under normal conditions of use.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity No additional information available

12.2. Persistence and Degradability No additional information available

12.3. Bioaccumulative Potential No additional information available

12.4. Mobility in Soil No additional information available

12.5. Other Adverse Effects

Other Information : Avoid release to the environment.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste Treatment Methods

Waste Disposal Recommendations: Dispose of waste material in accordance with all local, regional, national, and international regulations.

Ecology - Waste Materials: Avoid release to the environment.

SECTION 14: TRANSPORT INFORMATION

14.1. In Accordance with DOT Not regulated for transport

14.2. In Accordance with IMDG Not regulated for transport

14.3. In Accordance with IATA Not regulated for transport

SECTION 15: REGULATORY INFORMATION

15.1 US Federal Regulations Neither this product nor its chemical components appear on any US federal lists.

15.2 US State Regulations Neither this product nor its chemical components appear on any US state lists.

SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

Revision Date : 04/13/2016

Other Information : This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200

GHS Full Text Phrases:

Acute Tox. 3 (Oral)	Acute toxicity (oral) Category 3
H301	Toxic if swallowed

Carprieve Caplets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.

SDS US (GHS HazCom)